Fucoidan Independently Enhances Activity in Human Immune Cells and Has a Cytostatic Effect on Prostate Cancer Cells in the Presence of Nivolumab |
| |
Authors: | Ah Young Park Imane Nafia Damien N. Stringer Samuel S. Karpiniec J. Helen Fitton |
| |
Affiliation: | 1.Marinova Pty Ltd., Cambridge, TAS 7170, Australia; (D.N.S.); (S.S.K.); (J.H.F.);2.Explicyte Immuno-Oncology, 33000 Bordeaux, France;3.RDadvisor, Hobart, TAS 7006, Australia |
| |
Abstract: | Fucoidan compounds may increase immune activity and are known to have cancer inhibitory effects in vitro and in vivo. In this study, we aimed to investigate the effect of fucoidan compounds on ex vivo human peripheral blood mononuclear cells (PBMCs), and to determine their cancer cell killing activity both solely, and in combination with an immune-checkpoint inhibitor drug, Nivolumab. Proliferation of PBMCs and interferon gamma (IFNγ) release were assessed in the presence of fucoidan compounds extracted from Fucus vesiculosus, Undaria pinnatifida and Macrocystis pyrifera. Total cell numbers and cell killing activity were assessed using a hormone resistant prostate cancer cell line, PC3. All fucoidan compounds activated PBMCs, and increased the effects of Nivolumab. All fucoidan compounds had significant direct cytostatic effects on PC3 cells, reducing cancer cell numbers, and PBMCs exhibited cell killing activity as measured by apoptosis. However, there was no fucoidan mediated increase in the cell killing activity. In conclusion, fucoidan compounds promoted proliferation and activity of PBMCs and added to the effects of Nivolumab. Fucoidan compounds all had a direct cytostatic effect on PC3 cells, as shown through their proliferation reduction, while their killing was not increased. |
| |
Keywords: | fucoidan Nivolumab human peripheral blood mononucleocytes prostate cancer PC3 |
|
|